{"id":{"repo_id":"usf","oai_identifier":"oai:digitalcommons.usf.edu:etd-3901"},"canonical_url":"https://search.ndltd.org/etd/usf/oai:digitalcommons.usf.edu:etd-3901","repository":{"repo_id":"usf","name":"University of South Florida","base_url":"https://digitalcommons.usf.edu/do/oai/"},"display":{"title":"The Role and Regulation of Argininosuccinate Synthase in Endothelial Function","abstract":"While cellular levels of arginine greatly exceed the apparent Km for endothelial nitric oxide synthase (eNOS), nitric oxide (NO) production is limited by availability of arginine. Results from this work have provided a unique understanding of endothelial NO production, showing that arginine regeneration, that is the recycling of citrulline back to arginine by argininosuccinate synthase (AS) and argininosuccinate lyase (AL), defines the essential source of arginine for NO production. Using RNA interference analysis, selective reduction of AS expression was shown to directly correspond with a diminished capacity of endothelial cells to produce NO, despite saturating levels of arginine in the medium. In addition, the viability of AS siRNA-treated endothelial cells was compromised due to apoptotic cell death. AS expression was also investigated in response to two major vascular effectors. Tumor necrosis factor (TNF)-α, which is known to impair endothelial NO production, was shown to provoke a dose-dependent reduction of AS expression that corresponded to a decrease in NO production. Furthermore, TNF-α was shown to suppress AS expression through a NFκB mediated pathway, which involves three essential Sp1 elements in the proximal AS gene promoter. On the other hand, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, troglitazone and ciglitazone, which are known to elicit a vascular protective response against TNF-α effects, were shown to coordinately induce NO production and AS expression via a PPARγ response element in the distal AS gene promoter. Importantly, these PPARγ agonists were shown to restore AS expression and NO production following down-regulation by TNF-α, consistent with their vascular protective properties.","abstract_html":"While cellular levels of arginine greatly exceed the apparent Km for endothelial nitric oxide synthase (eNOS), nitric oxide (NO) production is limited by availability of arginine. Results from this work have provided a unique understanding of endothelial NO production, showing that arginine regeneration, that is the recycling of citrulline back to arginine by argininosuccinate synthase (AS) and argininosuccinate lyase (AL), defines the essential source of arginine for NO production. Using RNA interference analysis, selective reduction of AS expression was shown to directly correspond with a diminished capacity of endothelial cells to produce NO, despite saturating levels of arginine in the medium. In addition, the viability of AS siRNA-treated endothelial cells was compromised due to apoptotic cell death. AS expression was also investigated in response to two major vascular effectors. Tumor necrosis factor (TNF)-α, which is known to impair endothelial NO production, was shown to provoke a dose-dependent reduction of AS expression that corresponded to a decrease in NO production. Furthermore, TNF-α was shown to suppress AS expression through a NFκB mediated pathway, which involves three essential Sp1 elements in the proximal AS gene promoter. On the other hand, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, troglitazone and ciglitazone, which are known to elicit a vascular protective response against TNF-α effects, were shown to coordinately induce NO production and AS expression via a PPARγ response element in the distal AS gene promoter. Importantly, these PPARγ agonists were shown to restore AS expression and NO production following down-regulation by TNF-α, consistent with their vascular protective properties.","abstract_has_math":false,"creators":["Goodwin, Bonnie L"],"institution":"University of South Florida","degree_name":null,"degree_level":"Dissertation","degree_discipline":"Biochemistry and Molecular Biology","degree_department":null,"school":null,"contributors":["Duane C. Eichler, Ph.D.","Larry P. Solomonson, Ph.D.","Denise Cooper, Ph.D.","Huntington Potter, Ph.D.","Ken Wright, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2005,"date_issued":"2005-01-01T08:00:00Z","date_published":"2005-01-01T08:00:00Z","updated_at":"2026-11-19T08:34:58Z","subjects":["Nitric oxide","Enos","Endothelial","Apoptosis","tnf-alpha","ppar-gamma","American Studies","Arts and Humanities"],"languages":["EN-US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.usf.edu/etd/2902","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.usf.edu/etd/2902","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.usf.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.usf.edu%3Aetd-3901","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Duane C. Eichler, Ph.D.","Larry P. Solomonson, Ph.D.","Denise Cooper, Ph.D.","Huntington Potter, Ph.D.","Ken Wright, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Goodwin, Bonnie L"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2005-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biochemistry and Molecular Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation","Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of South Florida"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Nitric oxide","Enos","Endothelial","Apoptosis","tnf-alpha","ppar-gamma","American Studies","Arts and Humanities"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["EN-US"]},{"key":"dc:rights.license","label":"Dc Rights License","values":["default"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.usf.edu/etd/2902"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["While cellular levels of arginine greatly exceed the apparent Km for endothelial nitric oxide synthase (eNOS), nitric oxide (NO) production is limited by availability of arginine. Results from this work have provided a unique understanding of endothelial NO production, showing that arginine regeneration, that is the recycling of citrulline back to arginine by argininosuccinate synthase (AS) and argininosuccinate lyase (AL), defines the essential source of arginine for NO production. Using RNA interference analysis, selective reduction of AS expression was shown to directly correspond with a diminished capacity of endothelial cells to produce NO, despite saturating levels of arginine in the medium. In addition, the viability of AS siRNA-treated endothelial cells was compromised due to apoptotic cell death. AS expression was also investigated in response to two major vascular effectors. Tumor necrosis factor (TNF)-α, which is known to impair endothelial NO production, was shown to provoke a dose-dependent reduction of AS expression that corresponded to a decrease in NO production. Furthermore, TNF-α was shown to suppress AS expression through a NFκB mediated pathway, which involves three essential Sp1 elements in the proximal AS gene promoter. On the other hand, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, troglitazone and ciglitazone, which are known to elicit a vascular protective response against TNF-α effects, were shown to coordinately induce NO production and AS expression via a PPARγ response element in the distal AS gene promoter. Importantly, these PPARγ agonists were shown to restore AS expression and NO production following down-regulation by TNF-α, consistent with their vascular protective properties."]},{"key":"dc:title","label":"Title","values":["The Role and Regulation of Argininosuccinate Synthase in Endothelial Function"]}]}],"canonical_facts":{"dc:contributor":["Duane C. Eichler, Ph.D.","Larry P. Solomonson, Ph.D.","Denise Cooper, Ph.D.","Huntington Potter, Ph.D.","Ken Wright, Ph.D."],"dc:creator":["Goodwin, Bonnie L"],"dc:date":["2005-01-01T08:00:00Z"],"dc:description":["While cellular levels of arginine greatly exceed the apparent Km for endothelial nitric oxide synthase (eNOS), nitric oxide (NO) production is limited by availability of arginine. Results from this work have provided a unique understanding of endothelial NO production, showing that arginine regeneration, that is the recycling of citrulline back to arginine by argininosuccinate synthase (AS) and argininosuccinate lyase (AL), defines the essential source of arginine for NO production. Using RNA interference analysis, selective reduction of AS expression was shown to directly correspond with a diminished capacity of endothelial cells to produce NO, despite saturating levels of arginine in the medium. In addition, the viability of AS siRNA-treated endothelial cells was compromised due to apoptotic cell death. AS expression was also investigated in response to two major vascular effectors. Tumor necrosis factor (TNF)-α, which is known to impair endothelial NO production, was shown to provoke a dose-dependent reduction of AS expression that corresponded to a decrease in NO production. Furthermore, TNF-α was shown to suppress AS expression through a NFκB mediated pathway, which involves three essential Sp1 elements in the proximal AS gene promoter. On the other hand, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, troglitazone and ciglitazone, which are known to elicit a vascular protective response against TNF-α effects, were shown to coordinately induce NO production and AS expression via a PPARγ response element in the distal AS gene promoter. Importantly, these PPARγ agonists were shown to restore AS expression and NO production following down-regulation by TNF-α, consistent with their vascular protective properties."],"dc:identifier":["https://digitalcommons.usf.edu/etd/2902"],"dc:language":["EN-US"],"dc:rights.license":["default"],"dc:subject":["Nitric oxide","Enos","Endothelial","Apoptosis","tnf-alpha","ppar-gamma","American Studies","Arts and Humanities"],"dc:title":["The Role and Regulation of Argininosuccinate Synthase in Endothelial Function"],"thesis:degree_discipline":["Biochemistry and Molecular Biology"],"thesis:degree_level":["Dissertation","Ph.D."],"thesis:institution_name":["University of South Florida"]},"updated_at":"2026-11-19T08:34:58Z"}